Acuitive Technologies Enters Sport Medicine Market - CITRESPLINE™ & CITRELOCK™

ALLENDALE, NJ., March 4th, 2021

Acuitive Technologies Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITRESPLINE™ and CITRELOCK™ Ligament Reconstruction Devices using their patented CITREGEN™ biomaterial technology, a market disruptive bioresorbable synthetic polymer. 

Acuitive Technologies Granted FDA 510(k) Clearance for CITREFIX™ Knotless Suture Anchor

ALLENDALE, NJ., February 11th, 2021

Acuitive Technologies today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITREFIX™ Knotless Suture Anchor System with CITREGEN™ material technology, a new generation bioresorbable synthetic polymer.

Acuitive Technologies Granted FDA 510(k) Clearance for CITREGEN™ CITRELOCK™ Tendon Interference Screw System

ALLENDALE, NJ., October 21st, 2020

Acuitive Technologies today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITRELOCK™ Interference Screw System with CITREGEN™ material technology, a new generation thermoset bioresorbable synthetic polymer now FDA cleared. 

Acuitive Technologies Collaborates with Ireland-Based Research Institute, CÚRAM

GALWAY, IRELAND

Through their collaboration with CÚRAM, Acuitive Technologies Inc. has demonstrated the scientific potential of their paradigm-changing bioactive CITREGEN™ platform technology to expedite tissue healing and mitigate the problems associated with currently marketed biodegradable devices for numerous musculoskeletal applications